COGNITIVE · Injectable
Delta Sleep Inducing Peptide.
Deep sleep restoration peptide
How it works
Class & mechanism.
In short
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit blood in 1974 and also present in human cerebrospinal fluid. It is studied for its potential to increase slow-wave (delta) sleep depth and to help regulate the HPA axis, potentially lowering stress-driven cortisol output. Research findings have been mixed — some pilot studies report benefits for sleep, pain, and mood, while other researchers have described results as inconsistent, and it remains an unapproved research compound.
Class
Endogenous Neuropeptide (Sleep-Regulating)
Mechanism
Delta Sleep Inducing Peptide (DSIP) is a natural nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood in 1974. It influences sleep architecture primarily by modulating delta-wave (slow-wave, stage 3–4) sleep, acting on hypothalamic and limbic structures via receptors that remain only partially characterized. DSIP also exerts regulatory effects on the HPA axis — attenuating stress-driven cortisol and ACTH hypersecretion — and influences circadian rhythms of locomotor activity, intracerebral neurotransmitters, and plasma protein concentrations. Its amphiphilic structure enables ready passage through the blood-brain barrier.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
DSIP was discovered by injecting a sleeping rabbit's blood into an awake rabbit — and the awake rabbit reportedly fell asleep within minutes. That single experiment launched decades of sleep peptide research, and the molecule is naturally present in human cerebrospinal fluid.
Benefits
What it does.
May increase slow-wave (delta) sleep depth and continuity — the most restorative sleep stage
May attenuate stress-related HPA axis hyperactivation, reducing cortisol and ACTH excess
Small clinical pilot studies reported analgesic properties and a reduction in depressive symptoms
Preliminary evidence suggests it may reduce withdrawal symptoms in alcohol and opiate detoxification protocols
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
DSIP is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. DSIP is not FDA-approved for treating insomnia, sleep disorders, or any other use. This page does not recommend, endorse, or prescribe any compound for human use. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
In a double-blind study of 16 chronic insomnia patients, intravenous DSIP (25 nmol/kg) on 3 consecutive nights significantly improved subjective sleep quality and increased delta-wave sleep duration versus placebo.
SOURCE · Schoenenberger et al., European Neurology / Sleep Research (Basel)
DSIP administered IV over 10 days (5 daily + 5 every 48–72h) to 7 patients with chronic migraine, tinnitus, and psychogenic pain significantly lowered pain levels in 6/7 patients and produced a simultaneous significant reduction in concomitant depressive states.
SOURCE · PubMed pilot clinical study, Neuropsychobiology
Animal studies demonstrated DSIP counteracts experimentally induced stress situations, normalizes circadian locomotor rhythms, and reduces plasma cortisol concentrations — suggesting a primary role in stress-sleep coupling.
SOURCE · Borbély & Tobler, Progress in Neurobiology (1980s review)
Protocol
How to use it.
Dosing
100–500 mcg subcutaneous injection, administered 30–60 minutes before bed. No standardized guidelines exist. Some practitioners use DSIP only on nights of acute sleep disruption rather than nightly; others use short cycles.
Cycle
2–4 week cycles are typical, with breaks of equal duration. Can also be used as-needed for travel, schedule disruption, or acute insomnia rather than as a nightly protocol.
Contraindications
When to skip it.
Limited long-term human safety data. Avoid in pregnancy. Use caution in individuals with HPA axis disorders (Cushing's, Addison's) or those on corticosteroid therapy. Research on DSIP has been conflicting — Professor Borbély called results 'negative or ambiguous'; the original researcher (Schoenenberger) attributed negative findings to funding gaps rather than inefficacy.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| PCAC Review July 2026 | 🔴 At Risk | Awaiting PCAC — 503A eligibility review | PCAC July 24, 2026 |
Delta Sleep-Inducing Peptide (DSIP). Removed from Category 2 (Apr 23, 2026). Under PCAC review July 24. Gray zone until formal 503A listing.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for Delta Sleep Inducing Peptide, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Delta Sleep Inducing Peptide pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $99–$149 USD